Nimotuzumab Injections

Nimotuzumab Injections Specification

Salt Composition
Nimotuzumab

Origin
Biotechnological

Dosage Form
Injection

Indication
Head and Neck Cancer, Glioma, other EGFR expressing tumors

Ingredients
Nimotuzumab 50mg (per vial), Excipients

Application
Cancer Therapy

Physical Color/Texture
Clear to slightly opalescent liquid

Fermentation Smell
Odorless

Shelf Life
24 months from manufacturing date

About Nimotuzumab Injections

Nimotuzumab:-

Targeted therapy in the treatment of cancer has significantly improved the clinical benefits over conventional therapy in indications like head and neck, colorectal etc. Molecular targets such as epidermal growth factor (EGFR) have been well established in the treatment of various solid tumors. Screening for the molecular target and treating the patient with the respective targeted therapeutic agents with or without combination therapy had changed the treatment modalities in recent past. Nimotuzumab is a humanized monoclonal antibody binds to the extracellular domain of EGFR, and consequently inhibits tyrosine kinase activation. Nimotuzumab is the only-affinity optimized anti-EGFR monoclonal antibody exhibits superior safety profile among the class of anti-EGFR agents. Anti-tumor efficacy of nimotuzumab was well correlated with the level EGFR expression in tumors in vitro/ in vivo

Precise Cancer Therapy

Nimotuzumab Injection is manufactured through advanced biotechnology to specifically target EGFR-expressing cancer cells. Its precision reduces harm to healthy tissues, making it a preferred option in managing head and neck cancers, glioma, and certain other tumors. Healthcare professionals administer it by intravenous infusion in controlled environments, ensuring accurate dosage and patient safety.

Safe and Controlled Administration

Packaged in a high-quality glass vial, Nimotuzumab is designed for intravenous infusion only, under strict hospital protocols. This medicine must not be mixed with other drugs in the same infusion line to maintain its effectiveness and reduce the risk of adverse reactions. Its clear to slightly opalescent, odorless liquid ensures easy visual inspection for purity and safety.

Trusted Supply for Healthcare Institutions

Distributed by reliable dealers and wholesalers, Nimotuzumab comes with a minimum order requirementtypically five vialsto support hospital and oncology department stock needs. The products 24-month shelf life allows for practical inventory management, while compliance with Indian regulatory standards ensures trusted quality and efficacy.

FAQs of Nimotuzumab Injections:

Q: How is Nimotuzumab Injection administered in clinical settings?

A: Nimotuzumab Injection is administered as an intravenous infusion by healthcare professionals in hospitals or oncology centers, ensuring careful monitoring and appropriate dosing for cancer patients.

Q: What types of cancer can be treated with Nimotuzumab Injection?

A: This injection is indicated for the treatment of head and neck cancer, glioma, and other tumors that express the epidermal growth factor receptor (EGFR). Your oncologist will determine if it is suitable for your condition.

Q: When should Nimotuzumab be given during cancer therapy?

A: The timing and frequency of Nimotuzumab administration are determined by the treating oncologist based on the patients cancer type, progression, and response to previous treatments. It is a prescription-only medication used as part of a comprehensive treatment plan.

Q: Where can Nimotuzumab Injections be sourced, and who supplies them?

A: Nimotuzumab is supplied by authorized dealers, distributors, and exporters in India. Hospitals and oncology centers can obtain it through these channels with a minimum order quantity as advised by the supplier.

Q: What is the process for storing Nimotuzumab Injection to retain its stability?

A: This medicine should be stored as per the manufacturers recommendations, typically in a temperature-controlled environment, and used within 24 months from the manufacturing date to ensure optimal efficacy.

Q: How should Nimotuzumab be used with other medications during a treatment cycle?

A: Nimotuzumab should not be mixed with other drugs in the same infusion line. To prevent interactions and maintain its effectiveness, it must be infused separately, following hospital pharmacy protocols.

Q: What are the primary benefits of using Nimotuzumab Injection in cancer therapy?

A: Nimotuzumab offers a targeted approach by directly binding to EGFR-expressing cancer cells. This selectivity reduces collateral damage to normal tissue, potentially increasing treatment effectiveness while minimizing side effects.

Get Latest Price